<- Go Home
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Market Cap
$151.5M
Volume
202.9K
Cash and Equivalents
$46.0M
EBITDA
-$65.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$233.0K
Profit Margin
100.00%
52 Week High
$3.82
52 Week Low
$1.23
Dividend
N/A
Price / Book Value
3.94
Price / Earnings
-2.32
Price / Tangible Book Value
3.95
Enterprise Value
$106.1M
Enterprise Value / EBITDA
-1.63
Operating Income
-$66.2M
Return on Equity
102.94%
Return on Assets
-54.20
Cash and Short Term Investments
$46.0M
Debt
$693.0K
Equity
$42.6M
Revenue
$233.0K
Unlevered FCF
-$34.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium